Tenon Medical, Inc.
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
TNON$1.74-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash Flows from Operating Activities | ||
| Net loss | $(13,673) | $(15,581) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 3,845 | 4,145 |
| Depreciation and amortization | 408 | 199 |
| Provision for losses on accounts receivable | 41 | — |
| Amortization of operating right-of-use asset | 247 | 227 |
| Increase (decrease) in cash resulting from changes in: | ||
| Accounts receivable | (386) | (290) |
| Inventory | (52) | (139) |
| Prepaid expenses and other assets | 183 | (301) |
| Accounts payable | (64) | (117) |
| Accrued expenses | (171) | (99) |
| Operating lease liability | (256) | (227) |
| Net cash used in operating activities | (9,878) | (12,183) |
| Cash Flows from Investing Activities | ||
| Sales of short-term investments | — | 6,996 |
| Purchases of short-term investments | — | (493) |
| Purchases of property and equipment | (186) | (361) |
| Net cash (used in) provided by investing activities | (186) | 6,142 |
| Cash Flows from Financing Activities | ||
| Gross proceeds from issuance of Series A convertible preferred stock | 2,605 | — |
| Gross proceeds from issuance of Series B convertible preferred stock | 550 | — |
| Gross proceeds from issuance of common stock, prefunded warrants, and warrants | 4,500 | — |
| Gross proceeds from exercise of warrants under inducement agreement | 4,648 | — |
| Gross proceeds from issuance of common stock and warrants | — | 4,808 |
| Gross proceeds from issuance of common stock | 2,106 | 495 |
| Gross proceeds from issuance of convertible notes payable | — | 1,250 |
| Gross proceeds from exercise of warrants | 812 | 258 |
| Offering costs | (1,096) | (509) |
| Net cash provided by financing activities | 14,125 | 6,302 |
| Effect of foreign currency translation on cash flow | 46 | 38 |
| Net Increase in Cash and Cash Equivalents | 4,107 | 299 |
| Cash and Cash Equivalents at Beginning of Year | 2,428 | 2,129 |
| Cash and Cash Equivalents at End of Year | $6,535 | $2,428 |
| Cash at End of Year | $6,535 | $2,428 |
| Cash Equivalents at End of Year | $— | $— |
| Supplemental Disclosures of Cash Flow Information | ||
| Non-cash investment and financing activities: | ||
| Preferred stock issued upon conversion of debt and accrued interest, net of unamortized debt issuance costs | $1,186 | $— |
| Reclassification of deferred offering costs to additional paid-in capital | $367 | $— |
| Warrant modification costs | $992 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.